Angiotensin receptor blockers for management of hypertension

Southern Medical Journal

Volumn 103, Issue 7, 2010, Pages 669-673

  Catanzaro, Daniel F ^a   Frishman, William H ^b  

^a SUNY Downstate Medical Center   (United States)

^b NONE

Author keywords

angiotensin receptor blocker; angiotensin receptor blockers (ARBs) combination therapy; Angiotensin converting enzyme inhibitor; hypertension; renin angiotensin system

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; OLMESARTAN; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; PARADOXICAL DRUG REACTION; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 77954241805     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181e1e2da     Document Type: Review

References (33)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912.
2. Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13:S9-S20.
3. Hoit BD, Shao Y, Kinoshita A, et al. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 1995;95:1519-1527.
4. Silverstein RL, Ram CV. Angiotensin-receptor blockers: benefits beyond lowering blood pressure. Cleve Clin J Med 2005;72:825-832.
5. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-1052.
6. Laight DW. Therapeutic inhibition of the renin angiotensin aldosterone system. Expert Opin Ther Pat 2009;19:753-759.
7. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003;16:123-126.
8. Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol 2005;86:159-208.
9. Tomaki M, Ichinose M, Miura M, et al. Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. Thorax 1996;51:199-201.
10. Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003;3:311-317.
11. Contreras F, de la Parte MA, Cabrera J, et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003;10:401-408.
12. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
13. Branch, K. Aliskiren (Tekturna® ) for Hypertension. Pharmacotherapy update. Vol X;No. III, May/June 2007. Cleveland Clinic. Available at: https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/pdf/ Pharmaco-X-III.pdf. Accessed August 14, 2009.
14. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007;8:529-535.
15. van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006;106:367-372.
16. Otani H, Otsuka F, Inagaki K, et al. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008;149:2816-2825.
17. Shah NC, Pringle S, Struthers A. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. J Renin Angiotensin Aldosterone Syst 2006;7:20-30.
18. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
19. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187.
20. Williams B, Poulter NR, Brown MJ, et al; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-640.
21. Canadian Hypertension Education Program 2009. Available at: http:// www.hypertension.ca/chep/recommendations-2009/ Accessed August 14, 2009.
22. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-195.
23. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13(4 pt 1):418-426.
24. Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs 2008;68:373-381.
25. Lacourcière Y. A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J Int Med Res 2002;30: 366-379.
26. Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide: in moderate to severe hypertension. Drugs 2008;68:1465-1472.
27. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008;10(1 suppl 1):27-32.
28. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-364.
29. Littlejohn TW III, Majul CR, Olvera R, et al; Study Investigators. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel- group, 4 - 4 factorial study. Postgrad Med 2009;121:5-14.
30. Wright JT Jr, Bakris GL, Bell DS, et al. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich) 2007;9:842-849.
31. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-886.
32. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29.
33. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment-a review. Cardiovasc Diabetol 2009;8:18.